EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities

Laura Mateu-Arrom iD, Lluis Puig iD

Expert Review of Clinical Pharmacology · 02.04.2024 · 17 (4) · 363-379

DOI: 10.1080/17512433.2024.2340552 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 11.04.2024. Verfasst von Laura Mateu-Arrom und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de B…. Hauptthemen laut MEDLINE: Psoriasis, Arthritis, Psoriatic, Inflammatory Bowel Diseases, Biological Products. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 222 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor necrosis alpha (TNF) inhibitors, IL12/23 inhibitor, IL17 inhibitors, and IL23 inhibitors. AREAS COVERED: This review aims to describe the specific characteristics of these drugs in relation to psoriasis comorbidities, in order to facilitate decision-making in clinical practice. EXPERT OPINION: Some of the biological treatments can influence comorbidities, in some cases even improving them. Therefore, comorbidities are a key factor when deciding on one biological treatment over another. The development of new drugs is expanding the therapeutic arsenal for psoriasis. A high level of expertise in the field with a detailed knowledge of the characteristics of every drug is imperative to provide personalized medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisArthritis, PsoriaticInflammatory Bowel DiseasesBiological ProductsHumansComorbidity

Stichwörter der Autor:innen

IL17 inhibitorsIL23 inhibitorsPsoriasisTNF inhibitorsbiologic treatmentcomorbiditiesustekinumab

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Laura Mateu-Arrom, Lluis Puig

Zitieren

APA

Mateu-Arrom, L., & Puig, L. (2024). Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology, 17(4), 363-379. https://doi.org/10.1080/17512433.2024.2340552

Vancouver

Mateu-Arrom L, Puig L. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology. 2024;17(4):363-379. doi:10.1080/17512433.2024.2340552

BibTeX
@article{MateuArrom2024,
  author = {Mateu-Arrom, Laura and Puig, Lluis},
  title = {Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {363--379},
  doi = {10.1080/17512433.2024.2340552}
}
Kostenlos starten →